Company news

Roche Holding Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

April 13, 2026

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

March 30, 2026

Correction: Roche

March 24, 2026

Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

March 23, 2026

Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation

March 18, 2026

Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy

March 17, 2026

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

March 16, 2026

AI in Life Sciences Market, 2026-2040 Industry Trends and Global Forecasts - IBM, IQVIA and Oracle Lead Data Platforms While Roche, Pfizer and AI Startups Accelerate Drug Discovery Innovation

March 13, 2026

FUJIFILM Biotechnologies Appoints Christiane Bardroff as Chief Business Officer

March 12, 2026

Roche Annual General Meeting 2026

March 10, 2026

Pegasys (Roche, pharmaand) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F

March 10, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

March 9, 2026

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

March 6, 2026

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

March 5, 2026

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

March 5, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

March 2, 2026

Volta Labs Ignites AGBT 2026 with Major Product Launches and Industry-Shaping Partnerships

February 26, 2026

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

February 20, 2026

Zealand Pharma Announces Financial Results for the Full Year 2025

February 19, 2026

Change to the Roche Enlarged Corporate Executive Committee

February 17, 2026

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

February 16, 2026

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

February 7, 2026

ChemoMetec enters Letter of Intent with Roche Diagnostics

February 4, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

January 29, 2026

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

January 27, 2026

Frazier Life Sciences Appoints Charles Fuchs as Senior Advisor

January 26, 2026

Genentech More than Doubles Investment in Holly Springs, North Carolina Manufacturing Facility

January 20, 2026

Cytespace Africa Labs Expands Molecular Testing Capacity to Advance Clinical Trials Across Sub-Saharan Africa

January 20, 2026

Frédéric Prince to Succeed Christian Loss, Effective January 1st, 2026

January 2, 2026

FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma

December 22, 2025

Genentech Announces Agreement With U.S. Government

December 19, 2025

Health Canada authorizes TNKase® (tenecteplase) for the treatment of Acute Ischemic Stroke (AIS)

December 17, 2025

Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities

December 16, 2025

Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU

December 15, 2025

Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry’s broadest in vitro diagnostic menu

December 11, 2025

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

December 10, 2025

Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark

December 9, 2025

European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis

December 9, 2025

Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas

December 8, 2025

Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study

December 8, 2025

Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)

December 2, 2025

Veeva Announces Expanded Partnership with Roche

November 24, 2025

European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma

November 19, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer

November 18, 2025

Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche

November 12, 2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis

November 10, 2025

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 5, 2025

Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

November 3, 2025

Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus

November 3, 2025

Roche purchases shares in tender offer for 89bio, Inc

October 30, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 261 decks. Every deck is listed under its year.